Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

12.27 -0.04 (-0.32%)
Streaming Delayed Price Updated: 12:06 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50,142
Open 12.23
Bid (Size) 11.49 (1)
Ask (Size) 12.30 (1)
Prev. Close 12.31
Today's Range 11.42 - 12.30
52wk Range 2.760 - 13.20
Shares Outstanding 34,432,122
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
Nanobiotix reported melanoma study data showing JNJ-1900 delivered 47.4% response rate, 78.9% disease control, and 14.6 months survival. 
Via Benzinga
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga

Performance

YTD
+323.1%
+323.1%
1 Month
+36.3%
+36.3%
3 Month
+174.5%
+174.5%
6 Month
+225.5%
+225.5%
1 Year
+148.9%
+148.9%

More News

Read More
Why Bullish Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
SelectQuote Posts Better-Than-Expected Results, Joins Nutex Health, NIO, MINISO Group And Other Big Stocks Moving Higher On Thursday
Via Benzinga
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
Earnings Scheduled For April 2, 2025
Via Benzinga
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
From Nanobiotix S.A.
Via GlobeNewswire
Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden
Via Benzinga

Frequently Asked Questions

Is Nanobiotix S.A. - ADSs publicly traded?
Yes, Nanobiotix S.A. - ADSs is publicly traded.
What exchange does Nanobiotix S.A. - ADSs trade on?
Nanobiotix S.A. - ADSs trades on the Nasdaq Stock Market
What is the ticker symbol for Nanobiotix S.A. - ADSs?
The ticker symbol for Nanobiotix S.A. - ADSs is NBTX on the Nasdaq Stock Market
What is the current price of Nanobiotix S.A. - ADSs?
The current price of Nanobiotix S.A. - ADSs is 12.27
When was Nanobiotix S.A. - ADSs last traded?
The last trade of Nanobiotix S.A. - ADSs was at 09/19/25 12:06 PM ET
What is the market capitalization of Nanobiotix S.A. - ADSs?
The market capitalization of Nanobiotix S.A. - ADSs is 422.48M
How many shares of Nanobiotix S.A. - ADSs are outstanding?
Nanobiotix S.A. - ADSs has 422M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.